ONO-7746 Study in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy Adult Subjects
- Interventions
- Drug: ONO-7746
- Registration Number
- NCT00956371
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Brief Summary
The primary objective of this study is to evaluate the safety and tolerability of ONO-7746 in healthy adult subjects. The secondary objectives are to characterize the pharmacokinetic and pharmacodynamic profiles of ONO-7746.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
- Healthy non-smoking male or female subjects (18-55 years inclusive)
- Body mass index (BMI) of 19-35 kg/m² (inclusive)
- For females: postmenopausal, non-lactating and non-pregnant
Read More
Exclusion Criteria
- History or presence of clinically significant disease
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description P ONO-7746 - E ONO-7746 -
- Primary Outcome Measures
Name Time Method Safety and tolerability of ONO-7746 across ascending single doses study duration
- Secondary Outcome Measures
Name Time Method Characterization of PK and PD profiles of ONO-7746 study duration
Trial Locations
- Locations (1)
Austin
🇺🇸Austin, Texas, United States